WT1 and acute myeloid leukemia: In acute myeloid leukemia (AML), the WT1-targeting vaccine galinpepimut-S (GPS) achieved a median overall survival of >12 months versus 6 months in controls (REGAL phase III trial, NCT04229979), correlating with robust WT1-specific T-cell responses in 80% of patients [95].